Weill Cornell Medicine Urology
Weill Cornell Medicine Urology
Jim C. Hu, M.D.

Jim C. Hu, M.D.

Find a Physician


Quickly search our world-class physicians and faculty by keyword, location and insurance provider.


Recent WCM Urology Medical Publications

Dr. Jim Hu - Physician Profile

To make an appointment with Dr. Jim Hu at the LeFrak Center for Robotic Surgery at NewYork-Presbyterian Hospital / Weill Cornell Medicine in New York City, please call our office at (646) 962-9600.

In this video, Dr. Jim Hu speaks about his clinical expertise as a urologist specializing in the diagnosis and treatment of cancers of the urinary tract, including prostate, kidney, bladder and testicular cancers.

For more information on Dr. Hu, please visit his physician profile page.

Breaking News for Prostate Cancer

In May 2016, Dr. Jonathan Shoag with Drs. Mittal and Hu of Weill Cornell Medicine / NewYork-Presbyterian Hospital reported in the New England Journal of Medicine to demonstrate that the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (which did not report a benefit of PSA screening) was severely flawed.

Prostate Cancer Partial Gland Ablation - Webinar with Dr. Jim C. Hu

Jim C. Hu, M.D., M.P.H. discusses various minimally-invasive and non-surgical treatment options under the umbrella term of partial gland ablation.

Dr. Hu speaks about techniques & practical outcomes of various partial ablation procedures performed for men with prostate cancer, most notably the High Intensity Focused Ultrasound (HIFU) procedure, which is performed at Weill Cornell Medicine.

Incidence of Metastatic Prostate Cancer in Older Men Increases Following Drop in PSA Screening

The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest a correlation between the increase and a change in prostate cancer screening guidelines recommending against routine prostate-specific antigen (PSA) testing.

Incidence of metastatic prostate cancer has increased among older men as PSA screening declines (With Dr. Jim C. Hu)

The incidence of metastatic prostate cancer appears to be rising in men aged 75 years or older, according to results of a SEER analysis published in JAMA Oncology.

This increase may be linked to the U.S. Preventive Services Task Force (USPSTF) 2008 recommendation against routine PSA screenings in men aged 75 years or older and the 2012 recommendation against routine PSA screening regardless of age.

Infections After Prostate Biopsy Continue to Rise

Infectious complication rates following prostate biopsies continue to increase, despite decreased use of the procedures, a new study confirms.

Jim C. Hu, M.D., MPH, of Weill Cornell Medicine, and colleagues reported that the rates of infection within 30 days of prostate biopsy increased from 2.6% to 3.5% from 2011 to 2014 in New York State, based on data from patients of all ages and payment modalities. Complication rates were higher for transrectal than transperineal biopsies. Rates did not differ between initial and repeat biopsies.


Find a Physician FIND A PHYSICIAN

© 2016 Weill Cornell Medicine All rights reserved.